Showing 2631-2640 of 3069 results for "".
- Promius Pharma Launches Zenatane 30mg Dosehttps://practicaldermatology.com/news/promius-pharma-launches-zenatane-30mg-dose/2458977/Promius Pharma, LLC has announced that ZENATANE™(Isotretinoin Capsules USP) are now available in a 30mg dose. Zenatane, AB rated equivalent to Accutane 30mg, has been introduced in response to dermatologists who have continued to request this strength of the drug. <
- POWER Study Suggests EpiDuo plus Doxycycline May be an Alternative to Isotretinoinhttps://practicaldermatology.com/news/power-study-suggests-epiduo-plus-doxycycline-may-be-an-alternative-to-isotretinoin/2459000/Doxycycline 200 mg plus adapalene 0.1%/benzoyl peroxide 2.5% gel (D+A/BPO) is an alternative to isotretinoin in patients intolerant to, or unable or unwilling to take, oral isotretinoin, and is an option for treatment of severe nodular acne, according to a new study. Findings suggest that th
- Actavis Divests Rights to Doryx to Mayne Pharmahttps://practicaldermatology.com/news/actavis-divests-rights-to-doryx-to-mayne-pharma/2459007/Actavis will divest the US rights to its oral acne treatment brand Doryx and other assets related to the acne brand to Mayne Pharma, in a deal worth $50 million. Actavis currently holds the license for the distribution of Doryx in the US under a partnership between Warner Chilcott Plc, which was
- INC Research Signs Agreement to Perform FDA Due Diligence Audit of Regulatory Documents for Provectus Biopharmaceuticalshttps://practicaldermatology.com/news/20141014-inc_research_signs_agreement_to_perform_fda_due_diligence_audit_of_regulatory_documents_for_provectus_biopharmaceuticals/2459085/Provectus Biopharmaceuticals, Inc. has retained INC Research, a leading, global Phase I to IV contract research organization, to conduct an FDA due diligence audit of its regulatory documents for PH-10 and PV-10. The audit will be conducted in two phases, both of which are expected to be
- The ISDS Awards Scholarships to Young Doctors from Around the Worldhttps://practicaldermatology.com/news/20140917-the_isds_awards_scholarships_to_young_doctors_from_around_the_world/2459117/20 young doctors have been awarded generous scholarships from twenty leaders of the International Society for Dermatologic Surgery (ISDS) to attend an ISDS medical conference. This year, the scholarships were awarded to young doctors from Europe, Asia, Latin America (including Cuba), and
- AAD Announces Donation of Melanoma Exposed Program from Bristol-Myers Squibbhttps://practicaldermatology.com/news/20140609-aad_announces_donation_of_melanoma_exposed_program_from_bristol-myers_squibb/2459214/Bristol-Myers Squibb donated its Melanoma Exposed™ program to the American Academy of Dermatology (AAD). The donation, provided through a charitable grant, will be used to increase public awareness of skin cancer—including melanoma, the deadliest form of skin cancer—and expand t
- Valeant Pharmaceuticals Donates $250,000 to The National Coalition Against Domestic Violencehttps://practicaldermatology.com/news/20140317-valeant_pharmaceuticals_donates_250000_to_the_national_coalition_against_domestic_violence/2459314/Valeant Pharmaceuticals North America, LLC donated $250,000 to the National Coalition Again
- Doctors Issue New Treatment Guidelines for Skin Abscesses Caused By MRSAhttps://practicaldermatology.com/news/20140317-doctors_issue_new_treatment_guidelines_for_skin_abscesses_caused_by_mrsa/2459315/It has been more than 10 years since the clinical battle began with community-acquired methicillin-resistant Staphylococcus aureus (MRSA), and doctors are still grappling with how to diagnose, treat and prevent this virulent form of staph infection, which is immune to man
- Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2a Cellulite Study of Collegenase Clostridium Histolyticumhttps://practicaldermatology.com/news/20131024-auxilium_pharmaceuticals_inc_announces_first_patient_dosed_in_phase_2a_cellulite_study_of_collegenase_clostridium_histolyticum/2459430/Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully-integrated specialty biopharmaceutical company, today announced the first patient dosed in its Phase 2a study of collagenase clostridium histolyticum (or "CCH") for the treatment of edematous fibrosclerotic panniculopathy ("EFP"), commonly known
- Valeant to Help Raise Awareness of Domestic Violencehttps://practicaldermatology.com/news/20131002-valeant_to_help_raise_awareness_of_domestic_violence/2459444/Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) is partnering with the National Coalition Against Domestic Violence (NCADV) to help raise awareness of domestic violence. As p